Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Endometrial Neoplasms 2Carcinosarcoma 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Salivary Gland Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Endometrioid 1Breast Neoplasms 1

Interventions

Gemcitabine 5Cisplatin 5Oxaliplatin 4pembrolizumab 3Irinotecan 3Carboplatin 3Specimen Handling 2Radiosurgery 2Psychiatric Rehabilitation 2Observation 2Magnetic Resonance Spectroscopy 2Leucovorin 2Floxuridine 2Erlotinib Hydrochloride 2Cyclophosphamide 2Cetuximab 2Bortezomib 2Blood Specimen Collection 2trastuzumab deruxtecan 1tislelizumab 1spartalizumab 1sodium thiosulfate 1selpercatinib 1rucaparib 1repotrectinib 1pidilizumab 1pazopanib 1p53 peptide 264-272, human 1motexafin lutetium 1montanide ISA 51 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colonic Neoplasms × ceralasertib × Sarcoma × Clear all
NCT04704661 2026-05-13

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

National Cancer Institute (NCI)

Phase 1 Active not recruiting
51 enrolled
BreastGastrointestinalGynecologicHead & NeckSarcoma

Breast Neoplasms, Carcinosarcoma, Colonic Neoplasms, Neoplasm Metastasis, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡